P/E at 35.7 vs Industry's 37.5: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Discount Amid Sector Premiums

Sun Pharmaceutical Industries Ltd trades at a P/E of 35.72, marginally below the Pharmaceuticals & Biotechnology industry average of 37.46. This 4.6% discount contrasts with many large-cap peers that often command premiums in this sector, reflecting a valuation that is neither stretched nor deeply discounted. The sector’s elevated P/E is driven by growth expectations and innovation pipelines, yet Sun Pharma appears to be priced with a degree of caution. This valuation positioning invites the question: previously rated Buy, what is Sun Pharmaceutical Industries Ltd’s current rating? The premium or discount relative to peers often signals market expectations about earnings growth sustainability and risk factors.

Performance Across Timeframes: Momentum Shifts and Relative Strength

Examining the stock’s returns reveals a compelling divergence between short- and medium-term momentum. Over the past year, Sun Pharma has delivered an 18.78% gain, significantly outperforming the Sensex’s decline of 7.46%. This outperformance extends to longer horizons as well, with three-year and five-year returns of 67.57% and 144.02% respectively, dwarfing the Sensex’s 12.69% and 28.72% gains over the same periods. However, the recent one-week and one-month returns tell a more cautious story, with the stock down 1.99% and 2.79% respectively, though still outperforming the Sensex’s sharper declines of 1.99% and 4.40% in those intervals.

Interestingly, the three-month return of 6.47% surpasses the Sensex’s 1.53%, indicating a modest recovery or consolidation phase. The stock’s year-to-date return of 10.17% also contrasts with the Sensex’s negative 11.94%, underscoring resilience amid broader market weakness. This mixed performance profile raises the analytical question: is this a genuine recovery or a relief rally that will fade at the 50 DMA? The interplay between short-term weakness and medium-term strength is a key dynamic for investors to monitor.

Moving Average Configuration: Mixed Signals from Technicals

The technical picture for Sun Pharmaceutical Industries Ltd is nuanced. The stock currently trades above its 100-day and 200-day moving averages, signalling that the longer-term trend remains intact. However, it is below the 5-day, 20-day, and 50-day moving averages, indicating short-term weakness or consolidation. This configuration often suggests a recent pullback within a broader uptrend or a pause before a potential trend continuation. The intraday volatility of 92.8% further emphasises the stock’s sensitivity to market movements, despite a narrow trading range of Rs 7.75 on the day.

This technical setup prompts the question: is this a recovery or a dead-cat bounce? The interplay between short-term resistance and long-term support levels will be critical in determining the stock’s near-term trajectory.

Sector Context: Pharmaceuticals & Biotechnology Performance Snapshot

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings seasons. Out of 34 stocks that have declared results, 14 reported positive outcomes, 15 were flat, and 5 posted negative results. This distribution reflects a sector grappling with both growth opportunities and headwinds such as regulatory scrutiny and pricing pressures. Within this context, Sun Pharma’s performance stands out for its relative stability and resilience, especially given its large-cap status and market cap of ₹4,54,578 crore.

Given the sector’s mixed earnings landscape, the valuation discount for Sun Pharmaceutical Industries Ltd may reflect cautious optimism. This raises a further analytical inquiry: should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider? The sector’s overall health and individual stock dynamics remain intertwined factors.

Rating Context: From Buy to Hold

On 3 September 2026, Sun Pharmaceutical Industries Ltd’s rating was updated from Buy to Hold by MarketsMOJO. This reassessment reflects the evolving valuation-performance balance and the mixed signals from recent price action and sector results. The Mojo Score stands at 67.0, indicating a moderate confidence level in the stock’s prospects relative to its peers. The rating change invites investors to weigh the stock’s attractive long-term returns against the recent short-term volatility and sector uncertainties.

Conclusion: A Balanced Valuation with Mixed Momentum

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a slight valuation discount to its industry peers, with strong long-term returns but recent short-term volatility. The moving average configuration suggests a stock in consolidation, supported by longer-term trends but facing short-term resistance. Sector results are mixed, reflecting broader industry challenges and opportunities. The rating update from Buy to Hold underscores this nuanced outlook, balancing past performance with current market dynamics. Investors may find value in analysing these data points carefully — what is the current rating for Sun Pharmaceutical Industries Ltd?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today